Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 6/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111851 | 1.00 | AKR1C3 (0.43) | AKR1C3FAAHCTSBCTSSCTSK | |
| SCHEMBL27606539 | 0.86 | FAAH (0.54) | FAAHCTSBCTSSCTSKCHRM4 | |
| SCHEMBL20139213 | 0.86 | FAAH (0.54) | FAAHCTSBCTSSCTSKCHRM4 | |
| SCHEMBL9959713 | 0.85 | NOTUM (0.54) | AKR1C3FAAHCHRM4GRM1MAPT | |
| SCHEMBL18040024 | 0.85 | GFER (0.50) | FAAHCTSBCTSSCTSKCHRM4 | |
| SCHEMBL16825000 | 0.85 | GFER (0.50) | FAAHCTSBCTSSCTSKCHRM4 | |
| SCHEMBL27208377 | 0.85 | GFER (0.50) | FAAHCTSBCTSSCTSKCHRM4 | |
| SCHEMBL31111640 | 0.83 | CHRNB2 (0.46) | CTSBCTSSCTSKCHRM4GRM1 | |
| SCHEMBL26133615 | 0.81 | NOTUM (0.57) | AKR1C3CHRM4MAPTCHRM2CHRM1 | |
| SCHEMBL28094591 | 0.81 | AKR1C3 (0.40) | AKR1C3MAPTALDH1A1USP2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643967-B2 | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-09 | — | — | US | disclosed |
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-12 | — | — | US | disclosed |
| EP-3080124-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015088045-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008885-A1 | PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS TLR INHIBITORS | TLR9, TLR7, TLR1 | AKR1C3 3769/4885FAAH 2881/4885CTSB 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.